Kinnate Biopharma (KNTE): Price and Financial Metrics
GET POWR RATINGS... FREE!
KNTE Stock Price Chart Interactive Chart >
KNTE Price/Volume Stats
| Current price | $8.27 | 52-week high | $26.05 |
| Prev. close | $8.19 | 52-week low | $7.29 |
| Day low | $7.59 | Volume | 184,900 |
| Day high | $8.28 | Avg. volume | 156,084 |
| 50-day MA | $9.50 | Dividend yield | N/A |
| 200-day MA | $15.71 | Market Cap | 363.67M |
Kinnate Biopharma (KNTE) Company Bio
Kinnate Biopharma, Inc. operates as a biopharmaceutical company, which engages in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company was founded by Stephen W. Kaldor and Eric A. Murphy in January 2018 and is headquartered in San Diego, CA.
Latest KNTE News From Around the Web
Below are the latest news stories about Kinnate Biopharma Inc that investors may wish to consider to help them evaluate KNTE as an investment opportunity.
Kinnate Biopharma Inc. Selected to Deliver Oral Presentation on its RAF Inhibitor Candidate Program at the Virtual IASLC 2022 Targeted Therapies of Lung Cancer MeetingPresentation to focus on antitumor activity of KIN-2787 in preclinical models of human BRAF-alteration driven non-small cell lung cancerSAN FRANCISCO and SAN DIEGO, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it has been selected to deliver an oral presentation of preclinical dat |
Gabelli Convertible and Income Securities Fund Declares First Quarter Distribution of $0.12 Per ShareRYE, N.Y., February 09, 2022--The Board of Directors of The Gabelli Convertible and Income Securities Fund Inc. (NYSE:GCV) (the "Fund") declared a $0.12 per share cash distribution payable on March 24, 2022 to common stock shareholders of record on March 17, 2022. |
Kinnate Biopharma Inc. to Participate in the 11th Annual SVB Leerink Global Healthcare ConferenceSAN FRANCISCO and SAN DIEGO, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that its Chief Executive Officer Nima Farzan will provide a company overview at the 11th Annual SVB Leerink Global Healthcare Conference, being held virtually from February 14-18, 2022. Event: 11th Annual SVB Lee |
Kinnate Biopharma Inc. to Present Preclinical Data on its FGFR Inhibitor Candidate at the ASCO Gastrointestinal Cancers SymposiumPresentation to highlight data from preclinical studies of the company’s next-generation pan-FGFR inhibitor, KIN-3248, and its activity against acquired FGFR gatekeeper and molecular brake drug-resistance mutationsSAN FRANCISCO and SAN DIEGO, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, announced the |
Kinnate Biopharma Inc. Announces FDA Clearance of Investigational Drug Application for KIN-3248Planned initiation of Phase 1 clinical trial for KIN-3248 in 1H2022SAN FRANCISCO and SAN DIEGO, Jan. 18, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that the U.S Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for KIN-3248, a next-generat |
KNTE Price Returns
| 1-mo | 6.57% |
| 3-mo | 0.61% |
| 6-mo | -57.61% |
| 1-year | -64.78% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -53.33% |
| 2021 | -55.46% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...